Samatasvir

Samatasvir
Clinical data
Routes of
administration
Oral
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
KEGG
Chemical and physical data
Formula C47H48N8O6S2
Molar mass 885.062 g/mol
3D model (JSmol)

Samatasvir (IDX-719) is an experimental drug for the treatment of hepatitis C. It was originally developed by Idenix, and development has been continued by Merck & Co. following their acquisition of Idenix. Samatasvir has shown good results in Phase II trials.[1]

Samatasvir is a highly potent and selective inhibitor of the hepatitis C virus NS5A replication complex.[2] While it showed promising results when administered as monotherapy, it is probable that samatasvir would be marketed as a combination product with other anti-hepatitis drugs to increase efficacy and reduce the chance of resistance developing, as with most other novel treatments for hepatitis C currently under development. Trials of samatasvir in combination with other antiviral drugs such as simeprevir are also underway.[3]

See also

References

  1. Vince B, Hill JM, Lawitz EJ, O'Riordan W, Webster LR, Gruener DM, Mofsen RS, Murillo A, Donovan E, Chen J, McCarville JF, Sullivan-Bólyai JZ, Mayers D, Zhou XJ. A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4. Journal of Hepatology. 2014 May;60(5):920-7. doi: 10.1016/j.jhep.2014.01.003. PMID 24434503
  2. Bilello JP, Lallos LB, McCarville JF, La Colla M, Serra I, Chapron C, Gillum JM, Pierra C, Standring DN, Seifer M. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus. Antimicrobobial Agents and Chemotherapy. 2014 Aug;58(8):4431-42. doi: 10.1128/AAC.02777-13. PMID 24867983
  3. Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.